LONGBIO-B(01779): Oversubscribed rights issue option has been exercised.

Tianchen Biosciences-B (01779) announced that the exclusive sponsor and overall coordinator (representing itself and international underwriters) has fully exercised the oversubscription rights as stated in the prospectus on June 30, 2026 (Tuesday). This involves a total of 2.12895 million H shares, accounting for approximately 15% of the total number of shares available for subscription under the preliminary global offering before the exercise of oversubscription rights. The H shares to be issued as a result of the exercise of the oversubscription rights will be distributed by the company at a price of HK$96.06 per H share. The oversubscribed shares will be used to facilitate the delivery of some H shares to subscribers who have agreed to delay the delivery of their allocated H shares under the global offering.